• Home
  • Topics
    • Health Insurance Coverage
    • Medicare
    • Medicaid and CHIP
    • Blue Cross Blue Shield
    • Health Insurance Companies
    • Prescription Drugs and Pharmacy
    • Healthcare Policy and Law
    • Hospitals and Health Systems
    • Healthcare Business
    • Health Technology and AI
    • Senior Care
    • Public Health and Research
  • Guides
    • All Health Insurance Guides
    • Choosing a Health Insurance Plan
    • Individual Health Insurance
    • Family Health Insurance
    • High Deductible Health Plans
    • Short-Term Health Insurance
    • Self-Employed Health Insurance
    • Student Health Insurance
    • Low Income Health Insurance
    • Health Sharing Plans
  • Insurance Company List
  • About Us

Health Plan News

Timely Health Plan News and Commentary

Health Plan News
Home Hospitals and Health Systems Moleculera Labs Receives Grant from OCAST

Moleculera Labs Receives Grant from OCAST

Posted on July 7, 2015 Written by Editor

Moleculera Labs today announced the receipt of a two-year, $300,000 matching grant from the Oklahoma Center for the Advancement of Science and Technology (OCAST). This grant supports the development and clinical validation of new diagnostic testing panels to identify autoantibodies directed against neuronal antigens in patients experiencing neuropsychiatric disorders such as depression, bipolar disorder and schizophrenia. Such panels are intended to assist physicians in identifying the subset of patients whose symptoms may actually be caused by underlying treatable infection-triggered autoimmune and inflammatory responses.

Research by Madeleine Cunningham, Ph.D., Moleculera’s co-founder and Chief Scientific Officer, and her collaborators has led to development of the Cunningham Panelâ„¢, which measures relevant anti-neuronal antibodies and neuronal cell-activating antibodies circulating in the patient’s blood, as well as the activity of a key enzyme in the brain involved in the up-regulation of many neurotransmitters including dopamine. This test panel aids physicians in identifying individuals with PANDAS or PANS, thus enabling those children to receive appropriate anti-infective and/or immunological treatment that often results in a dramatic reduction or resolution of symptoms, without resorting to symptomatic control with neuropsychiatric drugs alone.

Related Coverage

  • Braxia Scientific Provides Update on Clinical Trials for Ketamine and Psilocybin Drug Development
  • Industry Clinical Trials for Ketamine and Psilocybin Drug Development

For more reporting on this topic, see our Hospitals and Health Systems news hub.

Filed Under: Hospitals and Health Systems

Recent News

  • Paytient Survey: 61% of Insured Workers Paid Cash Without a Claim November 13, 2026
  • BCBS of Texas Drops Medicare Advantage Plans for 2027 November 10, 2026
  • How the 8 Biggest Health Insurers Are Reshaping 2027 Coverage November 10, 2026
  • One Insurer Controls Half the Market in 15 States, AMA Finds November 9, 2026
  • Cigna, UnitedHealthcare and Molina Exit ACA Markets for 2027 November 9, 2026
  • Health Insurer MLR Rebates Fall by More Than Half in 2026 November 9, 2026
  • IRS Raises 2027 FSA Limit to $3,500, HSA Limits to $4,500 November 9, 2026
  • ACA Sign-Ups Fall in 41 States as Net Premiums Jump 58% November 9, 2026
  • Medicaid Managed Care Now Covers 78% of Enrollees, Federal Data Shows November 9, 2026
  • Medicare Advantage Plans Shrink in 29 States for 2027 November 9, 2026

Search Our Site

Categories

  • Blue Cross Blue Shield
  • Health Insurance Companies
  • Health Insurance Coverage
  • Health Technology and AI
  • Healthcare Business
  • Healthcare Policy and Law
  • Hospitals and Health Systems
  • Medicaid and CHIP
  • Medicare
  • Prescription Drugs and Pharmacy
  • Public Health and Research
  • Senior Care

Entity Map

Disclaimer

All content on Health Plan News and information provided on this website is for informational purposes only and is not intended as a substitute for advice from your physician or other healthcare professional. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. Always consult with a healthcare professional before starting any diet, exercise, or supplementation program, before taking any medication, or if you have or suspect you might have a health problem.

Copyright © 2026 - Privacy Policy - Terms of Use - Disclaimer